Catalio Capital Management

Tracked participation in 2 Atlas companies, with 1 explicitly attributed lead.

2portfolio companies

4round participations

1lead positions

$53Mled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Jul 2021Iambic TherapeuticsSeries A (oversubscribed)$53M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

LSLila SciencesScienceLila Sciences (website: lila.ai) builds what it calls an “operating system for science,” combining an AI reasoning…$1.3Bvaluation$1.1BraisedRecent roundsSeries A extension (NVIDIA-backed) · Oct 2025$115M · Abu Dhabi Investment Authority (ADIA) (subsidiary), Flagship Pioneering +2Series A · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) subsidiary, Altitude Life Science Ventures +7Lila Sciences—Oct 2025 → Oct 20251 roundParticipant—

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Jul 2021 → Oct 20233 rounds1 led—

DateCompanyRoundRaisedValuationRoleEvidence

Oct 10, 2025LSLila SciencesScienceLila Sciences (website: lila.ai) builds what it calls an “operating system for science,” combining an AI reasoning…$1.3Bvaluation$1.1BraisedRecent roundsSeries A extension (NVIDIA-backed) · Oct 2025$115M · Abu Dhabi Investment Authority (ADIA) (subsidiary), Flagship Pioneering +2Series A · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) subsidiary, Altitude Life Science Ventures +7Lila SciencesSeries A$350M—Participant

Source ↗

Oct 03, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B (oversubscribed)$100M—Participant

Source ↗

Oct 03, 2021ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B$100M—Participant

Source ↗

Jul 14, 2021ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries A (oversubscribed)$53M—Lead

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗